A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

BACKGROUND: Type 2 diabetes (T2D) is a progressive disease that often requires a patient to use multiple antihyperglycemic agents to achieve glycemic control with disease progression. Omarigliptin is a once-weekly dipeptidyl peptidase-4 inhibitor. The purpose of this trial was to assess the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Seung-Hwan, Gantz, Ira, Round, Elizabeth, Latham, Melanie, O’Neill, Edward A., Ceesay, Paulette, Suryawanshi, Shailaja, Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674832/
https://www.ncbi.nlm.nih.gov/pubmed/29110647
http://dx.doi.org/10.1186/s12902-017-0219-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674832/
https://www.ncbi.nlm.nih.gov/pubmed/29110647
http://dx.doi.org/10.1186/s12902-017-0219-x

Ejemplares similares